The Accelerating Clinical Trials in the EU (ACT EU) initiative was launched in January 2022 by the European Commission, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA). ACT EU is a multi-annual programme aiming to create a favourable environment for research and development in life sciences, through harmonisation, innovation and collaboration with stakeholders. ACT EU builds on momentum of the Clinical Trials Regulation (CTR) and the launch of the Clinical Trials Information System (CTIS) on 31 January 2022. The initiative will deliver on the clinical trial innovation recommendations of the EMA network strategy and the European Commission’s Pharmaceutical strategy for Europe.
The vision is to transform the EU into a region that supports clinical trial development and enables collaboration and innovation at all stages of the clinical research lifecycle. Seamless coordination among stakeholders, regulators and ethics committees will lead to more cross-border collaboration. The website for the ACT EU initiative has been launched and contains updates on the progress of ACT EU priority actions. Key resources include latest information on the multi-stakeholder platform; the implementation of the Clinical Trials Regulation; voluntary procedures in scientific advice and the Simultaneous national scientific advice (SNSA) pilot. The website also includes news and events on clinical trials related to ongoing activities of the European Medicines Regulatory Network. The website is available at https://accelerating-clinical-trials.europa.eu/